Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

← catalyst calendar

NCT07011719 · readout ≤ 620 d

Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

720estimated

Sites

159

Countries

Argentina, Australia, Canada +13

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-09-08

actual

When the study began enrolling

Primary completion

Apr 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2030

estimated

The whole study's end, after follow-up

First posted

2025-06-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-31

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Metastatic Clear Cell Renal Cell Carcinoma
Advanced Clear Cell Renal Cell Carcinoma

Interventions

Drug: Casdatifan — also filed as AB521
Drug: Cabozantinib
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1

measured up to approximately 33 months

Publications

PMID 42246926 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed